The Global Healthy Living Foundation is a 501(c)(3) non-profit organization with the mission to improve the quality of life for people living with chronic illness. Learn more about us here. Below are our core Advocacies.
Medical Conditions
On our radarWe are currently monitoring legislation and supporting patient access to care around the following chronic conditions:
Arthritis is inflammation of one or more of the joints. One of the most common causes of disability in the U.S., this disease can severely limit function and negatively impact quality of life
While commonly thought of as a really bad headache, migraine is in fact a chronic, debilitating, and often under reported neurological condition.
An inflammation of the membranes covering the brain and spinal cord. There are vaccines available to prevent most forms of meningitis.
Causes bone density to decrease, resulting in reduced strength and fragile bones.
Elevated cholesterol can cause build up in the arteries which can cause dire health consequences.
Trending topics
On our radarWe are actively educating legislators and regulators at the state and national level regarding the following access to care issues:
Research by patients, for patients. Powered by CreakyJoints.
As an arthritis patient, you can make a difference in the fight against arthritis and related conditions with this free app. Here’s how:
The absolute number one thing we wish the world knew about migraine is that it is NOT a headache. Headache is one of several disabling symptoms of migraine, which is a serious and debilitating neurological disease affecting over almost 40 million men, women and children in the United States and over 1 billion worldwide.1 […]
⇀ READ MOREDuring flu and cold season, patients are nearly 25 percent likelier to take too much of the over-the-counter painkiller acetaminophen — one of whose brand names is Tylenol, and which is an ingredient in hundreds of medications — than they are the rest of the year. That’s what researchers found when they studied 14,481 patients […]
⇀ READ MOREOn Dec. 1, the U.S. Food and Drug Administration approved the PCSK9 inhibitor evolocumab (Repatha) to prevent heart attacks and strokes. It is the first PCSK9 approved for these conditions in adults with cardiovascular disease, notes Amgen in a release. Many patients, who had already been receiving the best therapies available, remained at high risk […]
⇀ READ MOREAdults with hypertension can lower their blood pressure by consuming less sodium and sticking to the Dietary Approaches to Stop Hypertension (DASH) diet. That’s according to preliminary data presented at the American Heart Association’s Scientific Sessions 2017 in Anaheim. Researchers, led by Stephen Juraschek, of Beth Israel Deaconess Medical Center, studied 412 adults of varying […]
⇀ READ MOREMore than half of patients are denied approval for proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), according to research published in the journal Circulation. And that’s true even though many appear to meet labeled indicators, the data shows. “Although a combination of clinical characteristics increases the likelihood of approval, payer type is the most significant […]
⇀ READ MORE